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Abstract: Neutrophils are phagocytes of the innate immune system with prominent 
roles in host defense and are also believed to be important in autoimmune diseases such 
as rheumatoid arthritis (RA) by accumulating in inflamed joints and contribute to 
tissues destruction. Neutrophils differentiate in the bone-marrow and are mature cells 
when entering circulation with a cytoplasm packed with granules that contain toxic 
substances in addition to receptors that can be up-regulated to the cell surface during 
activation. Migration into the affected tissue is directed by mediators from the inflamed 
site which guides neutrophils along a chemotactic gradient and transfers the cell from 
resting- into a primed state. The inflammatory process triggers a systemic acute phase 
response characterized by the production of acute phase proteins (APP). The most 
prominent APP is serum amyloid A (SAA), the concentration of which can increase 
thousand fold in response to infection, aseptic inflammation or trauma. Patients with 
RA often have chronically elevated SAA in blood and joints and SAA has been 
implicated in the pathogenesis of RA. Recombinant SAA (rSAA) has been suggested to 
possess proinflammatory activities and act as a chemoattractant for neutrophils via a 
receptor called FPR2. A peptide (PBP10) with intracellular inhibitory activity was 
shown to allow discrimination between neutrophil signals mediated by FPR2 and the 
closely related FPR1. Next, the receptor specificity for rSAA was studied by use of 
PBP10 and another FPR2 specific inhibitor WRW4. rSAA affinity for FPR2 in 
transfected cell lines was corroborated and rSAA indeed activated primary human 
neutrophils. However, FPR2 was not responsible for mediating activation of primary 
human neutrophils by rSAA. Next, proinflammatory activity of rSAA was compared to 
that of endogenous SAA in circulation of RA patients. Using a sensitive marker for 
neutrophil activation in peripheral blood, endogenous SAA in circulation lacked 
proinflammatory activity and thus differed functionally from rSAA. Synovial 
neutrophils from patients with inflammatory arthritis and elevated SAA in joint fluid 
were next studied with respect to activation status. Synovial neutrophils displayed a 
surprisingly resting phenotype despite having transmigrated from peripheral blood to a 
compartment with endogenous SAA. Endogenous SAA, both in circulation and in 
joints, lack the proinflammatory properties present in the recombinant molecule. 
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ABBREVIATIONS 
Anti-CCP Autoantibodies directed toward citrullinated peptides 
APP  Acute phase protein 
APR  Acute phase response 
C3  Complement factor 3 
C5  Complement factor 5 
C5a   Complement factor 5a (split product from C5) 
CIA  Collagen induced arthritis 
CR3   Complement receptor 3 
CRP  C-reactive protein 
CGD   Chronic granulomatous disease 
DMARD Disease modifying anti-rheumatic drug 
fMLF   N-formylmethionyl-leucyl-phenylalanine 
FPR   Formyl peptide receptor  
G-CSF Granulocyte colony stimulating factor 
GPCR G-protein coupled receptor 
HDL  High-density lipoprotein 
IL   Interleukin 
LFA-1 Lymphocyte function-associated antigen 
LPS  Lipopolysaccharide 
MPO  Myeloperoxidase 
RA   Rheumatoid arthritis 
RF  Rheumatoid factors 
ROS   Reactive oxygen species 
SAA   Serum amyloid A 
SRs  Scavenger receptors 
 TLR   Toll-like receptor 
TNF   Tumour necrosis factor-α 
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INTRODUCTION 
Our body is constantly exposed to microbial threats that need to be 
combated. One arm of our immune system, called the innate immune system, 
is rapidly activated in an attempt to eradicate the invading danger by eliciting 
an inflammatory response with release of potent antimicrobial substances 
from inflammatory cells. Inflammation can also be activated aseptically in 
response to e.g., autoantigens, allergens or tissue damage. Inflammation is 
governed by a plethora of soluble signals from numerous sources in the 
affected tissues. Neutrophils, phagocytes of the innate immune system, arrive 
in vast numbers to an inflamed site after leaving the bloodstream and 
migrating out in the inflamed tissue guided by local gradients of 
chemoattractants. Neutrophils are armed with several antimicrobial 
substances that may also cause collateral damage to surrounding tissues. It is 
therefore vital that the activity of these cells is properly balanced. During the 
journey from blood to tissue, neutrophils will typically rearrange their surface 
flora of receptors and acquire an activated phenotype making cells primed for 
completing their antimicrobial mission. When the threat has been 
extinguished, neutrophils will gradually disappear from the site as 
inflammation is terminating. Usually, these processes run smoothly and 
homeostasis is rapidly recovered, but if inflammatory signals are altered or 
misprocessed, inflammation fails to terminate and may instead become 
chronic. Chronic inflammation characterizes many autoimmune diseases, e.g. 
rheumatoid arthritis (RA), and can be coupled to tissue damage. 
The inflammatory process, whether triggered by infection, tissue injury or 
autoimmune disease, also involves a systemic acute phase response where the 
liver synthesizes a number of distinct acute phase proteins that are released 
into circulation. Serum amyloid A (SAA) is one of the most prominent of 
these plasma proteins and its concentration can be chronically elevated in 
blood and joints of patients with RA. Since the protein has been described as 
a highly proinflammatory neutrophil chemoattractant, it has been implicated 
in the pathogenesis of RA in addition to serving as a reliable biomarker for 
monitoring disease activity.  
This thesis deals with SAA in inflammation and focuses on how 
recombinant SAA activate neutrophils and also addresses whether 
endogenous forms of this acute phase protein truly possess 
proinflammatory properties. Furthermore, whether SAA could be important 
in the pathology of RA or if it simply serves as a biomarker for ongoing 
inflammation is discussed. 
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INFLAMMATION 
In mammals, the immune system compromises innate and adaptive 
immunity; both parts are built of large numbers of cellular and humoral 
components involved in a complex interplay. The innate immune system is 
present from birth and considered more primitive and less specific than the 
adaptive immune system and in contrast also lacks immunological memory 
(1). Innate immunity forms the first line of defense against invaders; it is 
rapid and aims at recognizing microbes and at eliminate and/or delay their 
spreading until the slower-acting, but more fine-tuned adaptive immune 
system is mobilized. Aseptic inflammation triggered by non-infectious 
stimuli, e.g. autoantigens our allergens, will also activate the innate immune 
system. Infectious or non-infectious agents can  induce a fulminant immune 
response with production of proinflammatory mediators and activation of 
several cell types leading to the five cardinal signs of inflammation; rubor 
(redness), calor (increased heat), tumor (swelling), dolor (pain), and functio 
laesa (loss of function) (2-3). For example, the local cardinal sign of RA is a 
synovitis which is a joint effusion with massive infiltration of neutrophils and 
thickening of the synovia leading to restricted joint motion and pain 
(described below). Inflammation can also lead to systemic responses with 
induction of an acute phase response (APR) coupled to a release of acute 
phase proteins (APP).  
Given the power of inflammation, the process can be regarded as a double-
edged sword. It is of vital importance to effectively protect us against 
potentially lethal infections, but can also cause severe harm in itself if too 
forceful or too long-lasting. Whenever acute inflammation fails to terminate, 
inflammation can become chronic with involvement of the adaptive 
immunity and inflammatory diseases are often characterized by persistence of 
the inflammatory infiltrate, tissue hyperplasia and tissue destruction and 
scarring (4). Key cells of the innate immune response are monocytes, 
macrophages, dendritic cells and neutrophils. In particular neutrophils 
migrate in large quantities towards the site of tissue damage or infection and 
are the first cell to arrive at inflamed foci. Since neutrophils are particularly 
potent inflammatory cells, it is of crucial importance that the presence and 
activity of neutrophils is properly balanced, both temporarily and spatially.  
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NEUTROPHILS 
The principal task for neutrophils in our body is to combat invading 
microbes by phagocytosis and intraphagosomal killing. In humans, 
neutrophils are the most abundant leukocyte in circulation at concentrations 
around 1.8 – 7.5 x 109 cells/L, constituting about 60- 70% of circulating 
leukocytes. In contrast, neutrophils in mice are a minority population, making 
up only 20% of the total circulating white blood cells (5). During acute 
inflammation, neutrophils can be considered a hit and run type of cell, rapidly 
accumulating at the inflamed site in vast numbers, but also quick to disappear 
from the site once the immediate threat is cleared. The clearance is in part 
due to the fact that neutrophils are short lived cells that spontaneously 
undergo apoptosis after which they are rapidly cleared in visceral tissues like 
the liver and spleen (6). Neutrophils mature to fully differentiated cells in the 
bone marrow and their cytoplasm will be packed with storage organelles; i.e. 
granules, containing different matrix proteins and various membrane bound 
receptors (7). The granules constitute an arsenal of potent microbicidal 
compounds (proteolytic enzymes and antimicrobial peptides) that together 
with the reactive oxygen species (ROS) generated by the so called NADPH-
oxidase, make up the weaponry against intruders (8).  
Being professional phagocytes, neutrophils are equipped with receptors 
that recognize infectious agents directly, but also a variety of “danger 
signals” released from damaged tissue in response to e.g., infection, trauma 
or autoimmune disease (9-11). Chemotactic gradients of certain 
inflammatory mediators guide neutrophils into an inflamed site through the 
binding of specialized chemoattractant receptors. An acutely inflamed tissue 
is morphologically characterized by a dense infiltration of phagocytes the 
majority being neutrophils and since they are packed with a multitude of 
highly toxic compounds, they could contribute to tissue destruction in 
inflammatory diseases (12). Also, neutrophils can interact with other immune 
cells by cell–cell contact and secreted products, thereby suggesting 
neutrophils as immunological decision makers (13). In addition, neutrophils 
have been shown to possess regulatory roles during acute and chronic 
microbial infections e.g., by the production of the proinflammatory cytokine 
interleukin 8 (IL-8) (14) as well as the antiinflammatory cytokine interleukin-
10 (15-16).  
Thus, neutrophils are central in acute inflammation, but can also be present 
in vast numbers in diseases characterized by features of chronic 
inflammation. As will be discussed below, neutrophils are likely of 
importance for the pathology in rheumatic diseases (17).  
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From blood to tissue 
Of importance in studies of neutrophil function, is that their main stage for 
carrying out antimicrobial- and/or tissue destroying activities is not in 
circulation, but rather in the tissues. The trek from blood to tissue is a 
complex process whereby the cells undergo a number of functional changes. 
Extravasation alludes to the process whereby neutrophils leave the blood 
vessels and pass through the endothelium into the tissue (Fig. 1). 
Figure 1. Neutrophil transmigration from blood to tissue. Neutrophils sense signals from 
the inflamed tissues and start rolling on the endothelial surface. Interactions between the 
neutrophil and endothelial cells mediate neutrophil degranulation and rearrangement of 
cell surface receptors (e.g., cleavage of L-selectin and upregulation of CR3). The 
neutrophil crosses the endothelium by diapedesis and starts migrating through the tissue 
along chemotactic gradients towards the inflamed site.  
 In circulation resting neutrophils starts to roll along the vessel wall at a 
rate slightly slower than that of the blood flow; this population constitutes the 
marginal pool (1). Neutrophils of the marginal pool are in a dynamic 
equilibrium with circulating cells (18). Only in the postcapillary and 
collecting venules does blood flow slow down sufficiently to allow optimal 
tethering of leukocytes to endothelial cells. Therefore, in the majority of 
tissues and organs, leukocyte extravasation takes place in this segment of the 
circulatory tree (19). However, it is obvious that leukocytes can emigrate in 
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vascular beds that experience considerably higher shear forces, e.g. in the 
lung alveoli and into atherosclerotic lesions of arteries (20).  
Inflammatory mediators e.g., chemoattractants from the inflamed tissue, 
induce endothelial cells of the blood-vessels to upregulate adhesion 
molecules (e.g. E-selectin and P-selectin), on their luminal surface, making 
them sticky for free-flowing neutrophils (21-22). During the first stages of 
leukocyte-endothelial interaction, L-selectin and PSGL1 are the main 
neutrophil receptors involved. These interact with endothelial selectins which 
enable neutrophils to be captured by tethering and to roll along the 
endothelial surface. During the transition from rolling to firm adhesion on the 
endothelial cell layer the neutrophil will polarize and the expression of 
endothelial VCAM, which is involved in the later steps of firm adhesion and 
diapedesis, is also increased at this point (23). Lymphocyte function-
associated antigen (LFA-1) and CD11b/CD18 (CR3) on the neutrophil 
ensures cell arrest by binding VCAM and ICAM on the endothelium and 
extravasation into the tissue is initiated. The rearrangement of surface 
adhesion molecules is closely associated to neutrophil activation and priming 
(as discussed below) and both shedding of L-selectin and upregulation of 
CR3 and complement receptor 1 (CR1) (by degranulation) (24-27) are typical 
activation features that can be triggered by chemoattractants encountered 
during transmigration. However, this type of cellular activation may also be 
induced by other types of inflammatory mediators in vivo as well as in vitro 
(Paper III;(28)). Once the neutrophils have passed through the vessel, i.e. the 
endothelial layer, they will migrate towards the inflamed site via chemotaxis.  
During chemotaxis, neutrophils move towards increasing concentrations of 
chemoattractants which are recognized by chemoattractant receptors 
expressed on the cell surface (described below). The chemotactic “crawling” 
of the cells in the inflamed tissue depends on cytoskeletal reorganization that 
causes directional cell movements by continuous assembling and dissociation 
of actin filaments, and also on interactions between neutrophil integrins and 
the extracellular matrix (29). In addition, by degranulation neutrophils secrete 
a variety of matrix degrading enzymes (e.g., elastase) that could facilitate 
migration through extracellular matrix. 
Neutrophil priming 
During the passage from circulation to the tissue neutrophils undergo a 
number of changes, most notably represented by alterations in the flora of 
cell surface receptors. The change in receptor expression occurs mainly as a 
result of granule mobilization whereby the membranes of the various 
subcellular granules fuse with the plasma membrane. This is the case for e.g., 
 13 
complement receptors and chemoattractant receptors which surface 
expression are markedly increased after granule mobilizatio (30). Increased 
expression of chemoattractant receptors makes neutrophils increasingly 
responsive to stimulation by chemoattractants (as seen e.g., using production 
of free radicals as a read out system; Paper II) and this cellular state is 
normally referred to as a primed state.  Primed neutrophils typically lack 
surface L-selectin that is rapidly and efficiently down-regulated from the cell 
surface by ectodomain shedding induced by enzymatic activity of a 
metalloproteinase (ADAM 17) (31, 32 201). Most studies of neutrophil 
priming have been conducted on (resting) cells isolated from peripheral blood 
subsequently subjected to in vitro priming protocols. Frequently used in vitro 
priming agents for neutrophils are TNF and lipopolysaccharide (LPS) (33-
34).  Neutrophils that have encountered TNF or bacterial LPS are primed 
with respect to the oxidative response, but TNF or LPS per se does not 
activate the NADPH-oxidase in resting cells (35). The same principle applies 
for in vivo priming due to transmigration 
(Fig. 2). For experimental studies of in vivo 
transmigration and priming, a skin 
chamber technique is often employed (36). 
In brief, skin blisters were drawn on the 
volar side of the forearm by the use of 
suction chambers connected to a vacuum 
pump. The blister roofs were removed 
resulting in a superficial lesion of the skin. 
Thereafter a collection chamber was 
placed on the arm filled with autologuos 
serum. Over time chemotactic factors such 
as C5a and IL-8 will accumulate in this 
serum and attract neutrophils (36). After 
24 hours the chambers were removed from 
the arm and the chamber fluid was 
collected (Fig. 3). This procedure allowed 
analyses of mediators contained in the skin 
chamber fluid, as well as evaluation and 
characterization of transmigrated 
neutrophils. 
 
 
 
Figure 2. Transmigrated 
neutrophils are primed for 
NADPH-oxidase activation. 
Purified neutrophils from 
peripheral blood (Blood PMN) 
and skin chamber neutrophils 
from the same donor were 
stimulated by WKYMVM (5X10 
-8 M). Extracellular release of 
superoxide anion (ROS) was 
monitored with use of an 
isoluminol-amplified 
chemiluminescence system.   
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Figure 3. 
Method for obtaining in vivo 
transmigrated neutrophils. Skin 
chamber neutrophils were 
obtained according to (36). Skin 
blisters were induced on the 
volar side of the forearm of 
healthy volunteers by a suction-
chamber connected to a portable 
vacuum pump (A and B). After 2 
hours of continuous negative 
pressure, the top of the formed 
blisters were removed resulting 
in superficial lesions of the skin 
(C). Collection chambers with 
compartments corresponding to 
the lesions (D) were filled with 
autologous serum allowing neutrophils to migrate into the chamber fluid. The collection 
chambers were removed from the arm 24 hours later and the chamber fluid containing 
exudated neutrophils were aspirated (not shown).  
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THE ACUTE PHASE RESPONSE 
As described above, neutrophil recruitment from blood to tissue is a local 
manifestation of acute inflammation, but inflammation typically also triggers 
important systemic responses to the perceived insult, most notably the acute 
phase response (APR). The APR is a characteristic systemic reaction 
mediated by inflammatory stimuli (e.g. interleukin-1 (IL-1) and tumor 
necrosis alpha (TNF)) upon infection, direct tissue injury, or other threats to 
the body and it is characterized by changes in serum levels of a group of 
proteins called the acute phase proteins (APPs) (37-38). APPs are defined as 
proteins in which the plasma concentrations increase (positive) or decrease 
(negative) by at least 25 % during local or systemic disequilibriums (37). 
Several of these proteins aim to protect the body from infection and/or injury 
and to perpetuate homeostasis. The ratio between coagulation- and 
fibrinolytic APPs are balanced for formation and dissolution of fibrin clots 
(39) (40). C-reactive protein (CRP) and complement factor 3 (C3) are both 
APPs that facilitate phagocytosis by opsonisation of bacteria (41-42). In 
addition complement factors are APPs and activation of the complement 
system increases neutrophil recruitment by cleavage of complement factor 5 
(C5) to the potent chemoattractant complement factor 5a (C5a) (36). The 
complement system can also directly kill certain microbes by the formation 
of bacteriolytic membrane attack complexes (43). APPs are primarily 
synthesized by the liver and are clinically considered as good markers of 
ongoing inflammation, but since most of the proteins are produced in the 
liver, rather than directly in the affected tissue, they usually do not help to 
identify the specific injured tissue(s) (44).  
In case of prolonged exposure to stimulus or an inappropriate reaction to 
self molecules, inflammation may persist and lead to a chronic phase where 
the APR fails to switch off. Whether chronic elevations of some APPs have 
direct pathological consequences or if they are merely being biomarkers of 
inflammation is a matter of ongoing debate (45-46). One of the most 
prominent APPs is serum amyloid A (SAA), the concentration of which can 
increase 1000-fold in response to inflammation or infection (47). Levels of 
SAA may be chronically elevated in individuals with various inflammatory 
conditions such as atherosclerosis, diabetes, obesity, insulin resistance and 
above all rheumatologic diseases (48-49).  
Serum amyloid A  
SAA was first described in the mid seventies as a non-immunoglobulin 
protein purified from patients with systemic amyloidosis (50-51)and was later 
recognized as the precursor of reactive amyloidosis (52). The SAA proteins in 
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mammals are well conserved throughout evolution for at least 500 million 
years, indicating an important and beneficial role for survival and/or 
reproduction. That SAA is in fact essential is bolstered by the fact that 
homozygous mutations in a SAA gene resulted in prenatal lethality in mice 
(53).  
The function of SAA was for long not clear and it was described in the 
literature as a protein without a function (47). Since then, SAA has been 
implicated in a variety of biological processes, not least in lipid metabolism 
(54) but also as an opsonin for Gram-negative bacteria (55) and as a 
proinflammatory mediator and chemoattractant (discussed below). 
SAA is a family of apolipoproteins (47) with characteristic structural 
features (56). In circulation, SAA exists largely associated with high density 
lipoprotein (HDL) (54, 57), but may also be carried on very low-density 
lipoprotein particles, especially in circumstances where SAA levels are 
elevated (58) In humans, two major different forms of SAA are recognized, 
constitutive SAA (C-SAA) encoded by the gene SAA4 (59) and acute SAA 
(A-SAA) (60) encoded by SAA1 and SAA2. SAA3 is regarded as a 
pseudogene, but its product has in some studies been reported to be secreted 
from adipose tissue and the mammary gland (61-62).  
Regarding A-SAA, each 104-amino acid-residue primary product is 
processed to either a 103-residue or a 101-residue polypeptide by the loss of 
1 or 3 amino acids from the N-terminal (47). During inflammatory conditions 
the concentration of A-SAA can increase quickly 1000-fold in plasma, 
reaching levels > 600 mg/L ( ̴   50 µM), with peak values usually noticed 2 
days after induction (49, 63). Similar to the other APPs, SAA is 
predominantly produced by the liver, although extrahepatic production, i.e. 
from adipose tissue and synoviocytes, has been reported (63-64). The 
synthesis is largely regulated by inflammation-associated cytokines (IL-1, 
interleukin-6 (IL-6) and TNF), produced by endothelial cells, lymphocytes 
and in particular, activated monocytes and macrophages (44, 47, 65). When 
the inflammatory response resolves, SAA levels will decline after a few days. 
However, if inflammation fails to resolve, prolonged elevation of SAA levels 
is sustained due to overproduction of SAA, but also because the capacity of 
the liver to degrade SAA is believed to decrease during an APR or chronic 
inflammation (66).  
As described above, no clear consensus exists regarding the main function 
of SAA, but it has been implicated as an inflammatory mediator. This view 
gains support from the fact that SAA is often chronically elevated in 
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inflammatory diseases and various investigations (described below) have also 
shown SAA to be directly chemotactic for monocytes and neutrophils (67-68) 
by binding to a surface located chemoattractant receptor. (69) 
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CHEMOATTRACTANTS AND THEIR RECEPTORS 
For communication and recognition in a complex inflammatory 
environment, neutrophils are equipped with a wide variety of receptors, 
ranging from Toll-like receptors that recognize soluble danger signals, to 
immunoglobulin- and complement receptors that mediate phagocytosis. The 
recruitment of neutrophils to inflammatory foci is of fundamental importance 
for the body in response to infection and acute inflammation. This process is 
initiated and directed by exposure of cells to a biochemical gradient of 
chemoattractants, towards which the leukocytes migrate (5). 
Chemoattractants can be endogenous molecules such as C5a, chemokines 
(e.g., IL-8), or lipid metabolites (e.g., platelet activating factor). In addition, 
certain bacterial-derived substances are known to function as neutrophil 
chemoattractants, the best characterized being formylated peptides (e.g., N-
formyl-methionyl-leucyl-phenylalanine; fMLF) that are byproducts of 
bacterial metabolism (70-71). 
The chemoattractant receptors are all G protein-coupled receptors 
(GPCRs) and very important for neutrophil function as they mediate both 
directed cell migration and trigger other neutrophil effector functions 
(described below). The GPCRs span the membrane seven times and 
transduce information to the cell interior via a heterotrimeric, guanine 
nucleotide-binding protein (G-protein). Receptors that are coupled to G-
proteins have often been characterized with respect to their sensitivity to 
pertussis toxin, produced by the bacterium Bordetella pertussis (Paper I and 
II). These receptors are active in several organ systems in addition to the 
immune system, e.g. the central- and peripheral nervous system. Hence 
GPCRs are attractive targets for development of new drugs (72). 
As mentioned above, SAA has been shown to be a chemoattractant and the 
chemotactic receptor claimed to be responsible for its recognition is called 
formyl peptide receptor 2 (FPR2), a member of the FPR family of receptors. 
The FPR family, all being GPCRs comprises three different chemoattractant 
receptors that were originally named FPR, FPR like-1 (FPRL1) and FPRL2, 
but the nomenclature was recently changed to FPR1, FPR2 and FPR3 
respectively (73). Except for in papers I and II, which were published before 
the nomenclature changed, the new names will be used in this thesis. FPR1 
was first cloned in 1990 from differentiated HL-60 (74) cells (a human 
promyelocytic leukemia cell line) and shortly after, both FPR2 and FPR3 
were cloned by screening a cDNA library using FPR cDNA as a probe (75-
77). FPR1 and FPR2 possess 69% identity at the amino acid level and these 
receptors are widely expressed by various cells of both hematopoietic and 
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non-hematopoietic origin (70). FPR1 and FPR2 are expressed on both 
neutrophils and monocytes, while FPR3 is only expressed on monocytes (70). 
In mice, FPR1 directly contributes to proper immune defence against 
bacterial infections and mice deficient in the murine FPR homologue were 
found to be more susceptible to infection with Listeria monocytogenes (78). 
The FPRs are also believed to be involved in the pathogenesis of several 
human diseases, e.g. Alzheimer's disease, prion disease, juvenile 
periodontitis, airway inflammation and HIV (79-83). 
Given the multitude of chemoattractants and chemoattractant receptors that 
are involved in controlling inflammation, it is vital to possess adequate 
reagents (defined agonists and antagonists) and experimental systems in order 
to understand the roles played by specific molecules. 
Tools for studying the FPRs –agonists and antagonists 
The FPRs recognize a broad variety of ligands of exogenous and 
endogenous origins (81, 84). Essential for functional characterization of 
specific receptors and their ligands is the utilization of specific well-defined 
antagonist and inhibitors. Concerning the FPRs, only FPR1 and FPR2 are 
expressed by neutrophils and these two members are among the best studied 
human chemoattractant receptors with an ever expanding toolbox of specific 
agonists and antagonists available. The first described ligand binding FPR1 
was fMLF, originally derived from growing Eschericia coli (85). Thereafter 
it has been shown that formylated peptides also from other bacteria are 
effective at activating phagocytes via FPR1 (86). To date, several other 
ligands derived from bacteria and viruses as well as endogenous substances 
have been described (for details; see review (70)). Well defined specific 
antagonist of FPR1 is Boc-MLF and Boc-FLFLF, peptides with a bulky tert-
butyloxylcarbonyl (Boc) group at the N-terminus that sterically inhibits 
receptor activation. Another specific FPR1 antagonist is the cyclic 
undecapeptide Cys H (87).  
In addition to being a low affinity receptor for formylated peptides, FPR2 
recognizes several non-formylated peptides and is a promiscuous receptor 
that recognizes several different exogenous, endogenous and synthetic 
ligands with diverse structures (70). An established FPR2 specific agonist is 
the synthetic hexapeptide WKYMVM (88)which was identified by screening 
synthetic peptide libraries (89-90); this peptide has been used in this thesis for 
monitoring of FPR2 specific activities (Paper I and II). WRWWWW 
(WRW4) was the first specific antagonist for WKYMVM and thus blocks 
FPR2 (Paper II). This antagonist has later been shown to also antagonize the 
monocyte-specific FPR3 (91-92). 
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Aside from the above mentioned antagonists that all block receptor-ligand 
interactions there also exist inhibitors of these receptors that exert their action 
by blocking of intracellular signals. Phosphoinositide binding peptide 
(PBP10) is a ten amino acid long peptide derived from the PIP2 binding 
domain of gelsolin, coupled to a fluorophore rhodamin B. The presence of 
the fluorophore makes the peptide cell permeable and it inhibits intracellular 
signaling downstream of the receptor (93). PBP10 is receptor specific in that 
it inhibits signalling through FPR2, but not through FPR1 (Paper I). It 
should be mentioned that the inhibitory effect of PBP10 is not entirely 
restricted to FPR2 (Paper II (94)). Regardless, the ability of PBP10 to block 
FPR2-, but not FPR1 induced activity makes it a useful tool for determine 
FPR1 or FPR2 mediated neutrophil activities.  
Tools for studying the FPRs –read out systems for neutrophil activation 
Intracellular Ca2+ 
When an agonist binds to a GPCR, the receptor changes conformation 
which in turn activates a cascade of downstream signaling molecules e.g. 
phospholipases and protein kinases (second messengers) that typically leads 
to the release of Ca2+ from intracellular stores (95). The rise in cytosolic Ca2+ 
induces the opening of Ca2+-channels in the plasma membrane, which results 
in a sustained influx of Ca2+. A Ca2+ transient is an early detectable event in 
GPCR-mediated neutrophil activation and therefore intracellular Ca2+ 
measurements are a useful read-out system for studying ligand-receptor 
interactions in neutrophils or transfected cell lines (Paper I and II).  
Granule mobilization 
The mobilization of granules is not just a mechanism for release of toxic 
material to the phagosome during phagocytosis. Cellular activation induces 
mobilization of granules to the plasma membrane thereby providing the 
surface with additional receptors (96). The granules of the neutrophils; i.e. 
azurophilic granules, specific granules, gelatinase granules and secretory 
vesicles are different from each other with regards to size, density, membrane 
content, matrix composition and they are mobilized to the cell surface or to 
the phagosome in a hierarchical manner (97). The secretory vesicle, the first 
storage organelle to be secreted during neutrophil activation, is an important 
source of membrane bound receptors and can be mobilized already in the 
circulation (98). As mentioned above, alteration of the cell-membrane due to 
granule mobilization represents an important activation feature (Paper III 
and IV). 
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Production of reactive oxygen species  
Neutrophils are armed with a multitude of potent antimicrobial weapon 
systems, such as the NADPH-oxidase complex that will generate reactive 
oxygen species (ROS) when assembled. The oxidase complex consists of 2 
membrane-bound subunits (cytochrome b; constituted by gp91phox and 
p22phox) present in the plasma membrane and in the membranes of the 
specific granules, as well as at least 3 cytosolic components (p67phox, p47phox 
and p40phox) (99). Defects in the genes encoding subunits of the NADPH-
oxidase results in phagocytes incapable of ROS production and a disease 
called chronic granulomatous disease (CGD). CGD patients suffer from 
recurring bacterial and fungal infections and a variety of inflammatory 
conditions (100-101). Activation of the NADPH-oxidase occurs by assembly 
of cytochrome b and the cytosolic components of the oxidase to the 
membranes, thus forming a functional electron transporting enzyme system 
that converts O2 to O2- which can be further transformed into other ROS 
catalyzed by the azurophil granule enzyme myeloperoxidase (MPO).  
The NADPH-oxidase can be assembled both at intracellular membranes 
(typically, but not exclusively, the phagosomal membrane (102)) and in the 
plasma membrane, generating ROS that are released from the cell (8). 
Traditionally, ROS (especially the extracellular) have been considered 
harmful and culprits of tissue damage (103). However, several studies have 
shown that in the absence of ROS, inflammatory disease is in fact enhanced, 
indicating that ROS may somehow dampen inflammatory processes (102). 
For example, rodents with a defect phagocytic ROS production are 
susceptible to develop arthritis (104-105). Regardless of function, neutrophil 
activation by chemoattractants via GPCRs leads to extracellular release of 
ROS, which is thus a good read out for cellular activation (Paper I, II, III 
and IV).  
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PROINFLAMMATORY EFFECTS OF SAA 
Since the concentrations of APPs are so heavily raised during the APR and 
remain high during several inflammatory disease states, it has been argued 
that individual APPs in fact also drive inflammation. As such, APPs would 
not only be secondary to inflammation, but also a cause. Proinflammatory 
effects of SAA have been investigated in most part by the use of a 
commercially available recombinant SAA (rSAA) molecule (67-69, 106-112) 
that corresponds to human SAA1 except for the presence of three amino 
acids substitutions from SAA2. Each of the substitutions are described to 
exist in natural variants of SAA (113), but no naturally occurring allelic 
variant with identical sequence as rSAA has been described. Thus the rSAA 
protein is a hybrid molecule and is not identical to any of the human SAA 
isoforms.  
rSAA was first reported as a chemoattractant for phagocytic cells that 
induced migration, degranulation and adhesion of human monocytes and 
neutrophils (68). Subsequently, the signaling pathway was shown to be 
pertussis toxin sensitive indicating the involvement of a GPCR (67). A few 
years later the receptor specificity was determined by showing that a cell line 
transfected with FPR2 displayed chemotactic migration towards rSAA, 
stating SAA as the first endogenous ligand for FPR2 (69). We have 
confirmed these results by showing that rSAA induced Ca2+ transients in HL-
60 cells overexpressing FPR2 (Paper II), and the receptor specificity was 
further ascertained by the use of the specific FPR2 antagonist WRW4 
(described above) that efficiently blocked rSAA-induced Ca2+ transients in 
these cells. rSAA also activated the neutrophil NADPH-oxidase in a 
pertussis-toxin sensitive manner and the response could be primed by TNF or 
LPS demonstrating that the responsible receptor was stored in intracellular 
mobilizable granules. In agreement with these result also in vivo primed 
neutrophils (obtained by the skin chamber technique described above) 
responded with a primed oxidase response (Fig. 4).  
In primary neutrophils stimulated with rSAA, WRW4 however 
unexpectedly failed to inhibit Ca2+ transients (Paper II). Also the NADPH-
oxidase activation by rSAA was unaffected by WRW4; this pertained to both 
in vitro and in vivo primed neutrophils indicating that the responsible 
receptor  on primary neutrophils was not FPR2 (Fig. 4). The intracellular 
FPR2 inhibitor PBP10 partly blocked the NADPH-oxidase response after 
rSAA stimulation. The precise mechanism by which PBP10 interferes with 
some GPCRs has still not been determined, but it is reasonable that the 
signaling intracellular domains of the PBP10-sensitive receptors, i.e., FPR2 
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and the rSAA receptor are in some way structurally similar (Paper II). From 
these results we concluded that rSAA indeed activate human neutrophils, but 
that a GPCR receptor distinct from FPR2 is responsible (Paper II). In line 
with these findings, we have also shown that rSAA delay neutrophil 
apoptosis in vitro and that also this potentially proinflammatory effect was 
executed independently of FPR2 (114).  
Aside from its suggested role as a chemoattractant and activator of 
phagocytes, rSAA has also been shown to possess other proinflammatory 
effects using a variety of non-chemoattractant receptors, most notably Toll-
like receptors (TLRs) and scavenger receptors (SRs). When expressed in 
cervical cancer cell line (HeLa cells), TLR2 was shown to bind rSAA and 
subsequently activate NF-κB (115-116). TLR4 has also been proposed as an 
SAA receptor on primary murine peritoneal macrophages that upon 
stimulation with rSAA induced transcription of NO synthase (117). Two 
different scavenger receptors, SR-BI (118) and CD36 (119) were reported to 
function as endocytic rSAA receptors that trigger proinflammatory cytokine 
production when overexpressed in cell lines. SR-BI has also been 
demonstrated to mediate the cholesterol efflux function of HDL-associated 
SAA (120). In addition, the receptor for advanced glycation end-products 
(RAGE), mediated activation of NF-κB after stimulation of synovial 
fibroblasts with rSAA(109). 
Figure 4. rSAA activates the neutrophil NADPH-oxidase through a receptor distinct 
from FPR2. Skin chamber neutrophils were stimulated with WKYMVM (5X10 -8M) or 
recombinant SAA (10 µM) in the presence (dotted line) or absence (solid line) of the 
FPR2-specific antagonist WRW4. Extracellular release of superoxide anion was 
monitored with use of an isoluminol-amplified chemiluminescence system.  
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Despite lack of consensus regarding receptor specificity for rSAA, the 
picture has emerged of SAA as a multifunctional proinflammatory mediator 
that clearly activate neutrophils (Paper II and III). The majority of the 
studies mentioned above (including paper II) were carried out using the 
recombinant “consensus SAA molecule” which is not identical to the 
endogenous protein. It was thus of importance to study if endogenous SAA 
expressed during the APR was indeed proinflammatory and shared the 
neutrophil activating effects seen for rSAA. For this purpose we employed 
blood from patients with RA, that often display tremendously increased 
levels of endogenous SAA. Neutrophils from these patients were not 
activated despite the fact that they were surrounded by much higher SAA 
concentrations than was required to activate cells with rSAA (Paper III). 
When added to blood samples, rSAA clearly induced an activated phenotype 
of neutrophils, regardless of how much endogenous SAA that was present. In 
addition, purified acute phase SAA from human subjects neither activated 
neutrophils, nor stimulated cytokine production from macrophages (Paper 
III). These data provide strong evidence that endogenous SAA in circulation 
lacks proinflammatory activity and clearly differs from the recombinant form 
of the protein (Paper III).  
A known problem with bacterial-derived recombinant proteins is 
contamination with bacterial products (e.g., endotoxin) that could cause 
biological effects independent of the recombinant protein itself (45). The 
rSAA contained very low levels of endotoxin, however the possibility of 
other contaminating bacterial products can not totally be ruled out. 
Nevertheless rSAA activated neutrophils through a GPCR by inducing 
NADPH-oxidase activation and mobilization of intracellular Ca2+ and such 
activation is not mediated by endotoxin. A reason for the discrepancy 
between endogenous SAA in circulation and rSAA (Paper III) could 
potentially be explained by in what form the protein exists when presented to 
immune cells. Not only is SAA very prone to aggregation, but also to bind a 
variety of lipids (54). Hence proinflammatory forms of SAA could possibly 
be found outside of circulation. Since synoviocytes in rheumatic joints have 
been identified as an extrahepatic source of SAA (63), it has been tempting to 
speculate that SAA contributes directly to pathogenesis in arthritis and many 
investigators have argued that SAA is a proinflammatory mediator in affected 
joints of RA patients (67, 108, 111-112, 121-128). 
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ARTHRITIS 
Arthritis refers to a broad spectrum of conditions involving damage to the 
joints. Paleontologic studies have detected destructive joint conditions in 
dinosaurs in fossil records, and rheumatic joint destructions has been dated 
back some 6500 years from investigations of North American aboriginal 
skeletons (129). Different etiologies can cause arthritis and consequently 
arthritis present in various different forms and with diverse degrees of 
inflammation. Roughly, the inflammation process constitutes the cornerstone 
that determines the diagnosis and the treatment. The most common form of 
arthritis is osteoarthritis where inflammation is not an obvious feature; still 
this condition is the most frequent cause of slow progressive disability (130). 
In contrast, infectious arthritis caused by bacteria is characterized by massive 
inflammation. One example of bacteria-induced arthritis is septic arthritis 
induced by Staphylococcus aureus which causes a rapid destruction of joint 
cartilage and periarticular bone (131). 
A common form of arthritis usually presenting with inflammatory features 
is RA, affecting approximately 0.5-1% of the population with varying 
prevalence among different ethnicities. Caucasians are for instance more 
susceptible to the disease than Asians and Africans (132-133). Women 
present with RA more often than men, with a ratio of 3:1 (134), indicating 
that hormone levels are of importance (135). RA is regarded as a collection 
of syndromes rather than one disease; the main characteristic being 
symmetrical arthritis in peripheral joints (136). Clinical manifestations range 
from mild to rapidly progressive invasion of the synovium into the adjacent 
bone and cartilage resulting in erosive disease with massive tissue destruction 
(137). Other disease manifestations of RA can occur involving also other 
organs than the joints, e.g., the heart, lungs, eyes, kidneys or skin; these 
conditions are collectively referred to as extra-articular RA (138). Reactive 
amyloidosis (AA-amyloidosis) is an example of extra-articular RA and is a 
consequence of long, pronounced inflammation and present as deposits of 
placque in virtually any organ of the body (139). During recent years, 
increased mortality in cardiovascular disease due to accelerated 
atherosclerosis in patients with rheumatic diseases has been frequently 
reported (140-141). This could also be viewed as a form of extra-articular RA 
and the inflammation per se is suggested as the risk factor overriding 
traditional cardiovascular risk factors (142-143). 
A majority of RA patients have increased levels of rheumatoid factors 
(RF), i.e. autoantibodies, directed against the Fc portion of immunoglobulin 
G and serum concentration of RF has been found to correlate with disease 
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severity (144). Autoantibodies directed toward citrullinated peptides (anti-
CCP) have also been shown to correlate with disease severity and to be useful 
for diagnostic and therapeutic strategies especially in RA with recent onset 
(145-147). Moreover anti-CCP and RF are present in the synovial tissue, 
implying a possible direct pathogenic role (148-149). 
Synovial anatomy 
Synovial joints are composed of adjacent bones with articular cartilage 
connected by a fibrous joint capsule. The synovium is composed of a 
synovial lining layer and a synovial sublining layer. The synovial lining is 
built up by two major types of cells; macrophage-like- and fibroblast-like 
synoviocytes that are developed from different progenitor cells and 
subsequently express different surface markers (150-152). The synovial 
sublining is built up of loose connective tissue traversed by blood-vessels, 
lymph-vessels and nerve fibers. Major cell-types of the synovial sublining are 
fibroblasts, macrophages, mastcells and adipocytes. In contrast to e.g, the 
vascular endothelium, the synovial sublining lacks a continuous basal 
membrane (153). The space surrounded by the synovium is the synovial 
cavity which is filled with hyaluronan-rich synovial fluid formed by diffusion 
from the blood and supplemented with mucin produced in synoviocytes. The 
main function of the synovial fluid is to lubricate the cartilage and facilitate 
articular motion (153, 154). There are two different types of bone, trabecular 
(spongy) bone and cortical (compact) bone and the former appears porous 
with much room for blood vessels and bone marrow. The location of bone 
marrow inside the trabecular bone creates a physical opportunity for 
interaction between immune cells and bone cells. In RA, the destruction of 
cartilage and bone may lead to a state where the inflamed synovial tissue 
reaches the adjacent bone marrow by breaking the cortical barrier. Thus, the 
bone marrow could be considered an additional compartment of importance 
for the disease process in RA (194). 
Patophysiology of RA 
In RA joints, unknown factors trigger the immune system to react against 
cell- or tissue antigens leading to the production and release of inflammatory 
mediators that induce local inflammation. Gradual alterations in the normally 
thin and delicate synovial membrane will arise with thickening of the 
synovium, i.e. synovial hyperplasia, due to increased cell -accumulation, -
proliferation and increased angiogenesis. As inflammation proceeds, the 
synovium will develop and create a proliferation mass often referred to as a 
pannus (155-156). The pannus is an inflammatory active synovium that 
invade cartilage and bone with successive destruction by matrix degrading 
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enzymes, e.g. MMPs. A suggested source of MMPs is chondrocytes and 
synoviocytes (157), but also neutrophils are rich in MMPs suggesting that 
these cells could be important for the destruction (158-159) (Fig. 5).   
Figure 5. Schematic figure of an inflamed joint in RA. The inflamed synovium is 
infiltrated by an array of immune cells; i.e. T-cells, B-cells, fibroblasts and macrophages 
that act in concert with inflammatory mediators like TNF and IL-1. T-cells and B-cells are 
found in the synovium, but also in the synovial fluid. The joint cartilage is built up by 
chondrocytes that cover the articular bone. A pannus is formed at the junction between 
synovia and cartilage that gradually degrade tissues. Neutrophils are found the pannus-
cartilage junctions and in the synovial fluid, but are scarcely found in the synovium. 
Adapted from (213).  
The rheumatic joint cavity will be invaded by different inflammatory cells 
and it is not entirely clear which particular cell types that are of central 
importance for the initiation and progression of RA. The dominant view, 
however, is that the adaptive immune system plays the most important role in 
the pathogenesis of RA (160), but given the facts that innate immune cells 
such as neutrophils are often found in synovial fluid and that these are filled 
with potentially tissue-destroying enzymes, the adaptive immune system is 
not likely the full explanation. Supporting the role for adaptive immune cells 
in the pathogenesis of RA are mainly experimental results from animal 
studies that favor the hypothesis of RA being a T-cell driven disease. The T-
cell population in the inflamed joints is diverse, cytotoxic T-cells, T-helper 
cells and T regulatory cells all occur in the synovia as well as in the synovial 
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fluid. B-cells are in minority in the inflamed joint, but still seem important in 
the pathogenesis of RA, not least as producers of autoantibodies such as RF 
and anti-CCP (161). RF, being present in serum and in inflamed joints, form 
immune complexes that in turn can activate the complement with subsequent 
neutrophil activation which could contribute to joint destruction.  
Other immune cells e.g., monocytes/macrophages, dendritic cells and 
fibroblasts are present in the synovial tissues and possess widespread pro-
inflammatory, destructive, and remodeling capabilities (162-163). In addition 
stroma cells such as fibroblasts transform and proliferate in the inflamed 
joints and are found both at the pannus and in the synovial fluid (155-156, 
164).  
To halter the destructive process in the affected joints and prevent extra-
articular complications, early treatment with disease-modifying anti 
rheumatic drugs (DMARDs) focused on repressing inflammation is required 
(165). In the past decade, a group of new therapeutic drugs called biological-
response modifiers have remarkably transformed the field of rheumatology 
and dramatically improved patient outcomes (130). This is true in particular 
for the TNF-blockers. Blockade of TNF was first found to be effective in a 
mouse model of arthritis (166) and later shown to have effect also in human 
disease (167-168). TNF is a key cytokine in inflammation, important for host 
defense and immune responses, e.g. immune cell recruitment, -proliferation 
and -death just to mention a few roles (169). In RA more specific functions of 
TNF have been detected and it has been shown to induce matrix degradation 
and osteoclastogenesis (170) (171-173). TNF is also a key component in the 
cytokine cascade released during RA (174). Regardless of the exact 
mechanisms by which TNF-blockers mediate effects in vivo, these drugs lead 
to a decreased migration of leukocytes into joints and a reduction of 
angiogenesis (175). Given the central role of TNF and inflammation in host 
defense, it is not surprising that blocking of TNF can be hazardous and 
careful monitoring of patients are urged since the risk for infections, 
especially tuberculosis increases (176-178). Another treatment-strategy that 
has emerged lately and now challenge TNF-blockers as the number one in the 
treatment of RA is B-cell depletion (179). The last decade the field of 
rheumatology has been revolutionized by new treatments, in particular 
concerning RA, with several new drugs targeting multiple different cytokines 
or immune cells thereby highlighting the diverse nature of these diseases.   
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NEUTROPHILS IN RA 
Among the inflammatory joint diseases, septic arthritis is the most 
prominent example where neutrophils have been shown to have crucial roles, 
both for combating the infection per se (180), but also for contributing to the 
massive tissue destruction characteristic for this disease (181). Neutrophils 
can also be abundant in affected joints of aseptic arthritis, especially in the 
synovial fluid early in disease progression or during flares of joint diseases 
with massive joint effusions (153). Synovial biopsies from patients with 
recent onset of synovitis (one week to one month) indicate their presence in 
the synovium, although in later stages of the disease neutrophils are scarcely 
found at this site (182-184). Instead, the synovial fluid is the compartment 
where neutrophils are primarily found later in disease. The hallmark of RA is 
destruction of tissues (185) and neutrophils are certainly well endowed to 
inflict joint damage with an arsenal of toxic compounds (186). In addition, 
synovial fluid neutrophils have been reported at the pannus/cartilage borders 
(186-188), supporting the view that these cells could in fact be of importance 
for RA pathogenesis.   
As neutrophils are the dominant cell type in synovial fluid while often 
absent from the actual synovium, the question arise; how have these cells 
entered the synovial cavity? According to established tenets, neutrophils 
reach inflamed sites by transmigration from the blood through the inflamed 
synovium, finally reaching the synovial fluid, i.e. transmigration from blood 
to tissue. As described above, the cells found in synovial fluid would thus be 
expected to present with an activated phenotype and be primed (as described 
above) for further stimulation as is the case for in vivo transmigrated 
neutrophils obtained by the skin chamber model (189). We found that 
neutrophils from skin chambers showed full signs of priming (Paper IV) as 
detected by receptor exposure and NADPH-oxidase responses (Fig. 2). In 
stark contrast, we unexpectedly found neutrophils from synovial fluid to 
present with a relatively non-activated phenotype (Paper IV). These 
surprising results contradict several earlier studies showing the presence of 
activated neutrophils in synovial fluid (186, 190-192). Common for these 
studies is that synovial fluid neutrophils were further purified before 
analyses, which could possibly affect priming status in itself (24) (Paper IV).  
In agreement with earlier studies (193), we found relatively low levels of 
inflammatory cytokines and chemokines in synovial fluids, compared to the 
exudate fluid from the skin chambers applied on healthy subjects; a pattern 
that was especially pronounced for IL-1, IL-8 and TNF (Paper IV). In 
contrast, SAA levels were elevated in synovial fluid as compared to exudate 
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fluid, but still at very moderate levels as compared with serum SAA of RA 
patients (Paper III and IV). This pattern is very counter-intuitive if SAA 
should function as a chemoattractant guiding neutrophils to the inflamed 
joint, since migration typically proceeds against increasing concentrations of 
the chemoattractant. It is possible that the SAA found in circulation differs 
from that in an inflamed joint and that only the latter possess 
proinflammatory effects. However, our results with elevated levels of SAA in 
synovial fluid accompanied by non-activated neutrophils argue that SAA is 
hardly a potent mediator in inflamed joints. This conclusion is in accordance 
with the fact that endogenous SAA in circulation was unable to activate 
neutrophils (Paper III and discussed above). Together, our findings argue 
against direct proinflammatory activities of endogenous SAA. 
The unexpected presence of non-primed, i.e. resting neutrophils, in the 
synovial fluid raises several questions. First, since transmigration from blood 
to tissue normally prime neutrophils how do the neutrophils enter synovial 
fluid without getting primed? One tempting possibility is that neutrophils 
could reach the synovial cavity directly from the bone marrow instead of 
transmigrating from blood. Bone marrow has been proposed to be an 
additional compartment in the disease process of RA, since inflamed tissue in 
patients suffering of an erosive disease, i.e. destruction of cartilage and bone, 
physically connects with the bone marrow (194). Another possibility is that 
circulating neutrophils “leak” through synovial blood vessels without the 
regular activation. In fact, immature, incompletely developed blood vessels 
lacking periendothelial coverage have been found in RA synovia and such 
vessels would be leakier than mature vessels (195). Whatever route 
neutrophils use to reach the synovial cavity, it is clear that they reach this site 
in large numbers without being fully primed. It is however, still unclear what 
role neutrophils play in the aseptically inflamed RA joint. 
Animal studies have been undertaken to clarify the importance of 
neutrophils in RA showing for example that initiation and progression of RA-
like arthritis in mice depend on neutrophils (196). Another recent study 
showed that granulocyte colony stimulating factor (G-CSF) deficient mice 
were markedly protected from collagen-induced arthritis, the major murine 
model of RA (197). Moreover, neutrophil depletion attenuated already 
established collagen induced arthritis (CIA) demonstrating neutrophils as key 
effector cells that promote the progression of disease (198). It is clear that 
neutrophils have ability to inflict massive tissue damage also in human 
disease, and synovial fluid neutrophils has been suggested to phagocytose 
immune complexes (192) driving the release of powerful proteases.  
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To further highlight the role of neutrophils in inflammatory joint disease, 
examples from clinical situations can be used. Patients who develop Felty’s 
syndrome, defined by RA and the development of splenomegaly and 
neutropenia (199) usually experience a decrease in inflammatory activity and 
number of swollen joints as neutropenia proceeds (200). Occasionally, if 
these patients need treatment with G-CSF that increase release of neutrophils 
from the bone marrow, it is not unusual that arthritis reoccur (201). Another 
example stressing the role of neutrophils in inflammatory joint disease is 
uncovered when studying anti-inflammatory therapies aimed at inhibiting IL-
6. Blockade of IL-6 very efficiently decreases RA joint pathology and 
simultaneously induces prompt and potent suppression of neutrophil 
recruitment from the bone-marrow into peripheral blood (202). 
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SAA -PROINFLAMMATORY MEDIATOR OR BIOMARKER? 
As mentioned above, most reports describing SAA as an active mediator 
of inflammation have not employed endogenous SAA, but rather the 
recombinant hybrid molecule. Our data, showing clear functional differences 
between endogenous SAA and rSAA (Paper III and IV), with the former 
completely lacking proinflammatory effects, strongly argues against the view 
that SAA is an active participant in RA and other inflammatory diseases. 
However, one disease where SAA is doubtlessly directly involved is AA-
amyloidosis. This disease can complicate inflammatory disorders that are 
associated with a sustained APR; RA being the most prevalent with 
approximately 5 % of patients developing AA amyloidosis (203). AA-
amyloidosis is characterized by extracellular deposits of SAA, forming fibrils 
in β-sheets (204) that gradually disrupt the structure of tissues and organs 
leading to progressive organ dysfunction (203). The exact mechanism of how 
SAA is transferred into an amyloidogenic, i.e. aggregated form, in humans is 
not known, though several mechanisms have been suggested (205-206). It 
should be noted that amyloid formation as detected in biopsies from adipose 
tissue or kidneys is not encompassed by an inflammatory reaction (Johan 
Mölne, personal communication), arguing against the idea that SAA assumes 
a proinflammatory conformation by aggregation. If the primary disease 
causing amyloidosis is appropriately treated with sustained normalization of 
SAA levels, amyloid deposition is halted and existing amyloid deposits often 
resolve (207-208). Thus prolonged presence of high levels of endogenous 
SAA can directly contribute to complications associated with inflammatory 
disease. It is important to note that this could be accomplished without SAA 
being an active inflammatory mediator in itself and that SAA is not the cause 
of inflammation, but rather a consequence. 
Even if endogenous SAA lacks proinflammatory activity, the protein can 
still be of clinical importance as a biomarker for inflammatory disease. The 
ultimate biomarker should be an independent indicator and predictor of 
biological conditions that can be measured objectively and easy, both in 
health and disease. SAA has been suggested as the best marker available for 
the assessment of inflammatory joint disease but due to costly experimental 
testing, the monitoring of SAA for disease activity in RA is not a clinical 
routine. Compared with sedimentation rate or CRP, SAA correlates best with 
clinical disease activity in RA and ankylosing spondarthritis (209-210). Also, 
SAA was recently reported as a reliable biomarker for disease activity in 
Takayasu arterit, a chronic inflammatory vasculitis (211). Besides serving as 
a reliable biomarker in rheumatic disease, SAA has also been shown to be a 
biomarker in other diseases where inflammation is significant but 
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independent of autoimmune processes, such as different neoplastic disorders 
(212).  
Inflammatory diseases such as RA are very complex involving both 
adaptive- and innate immunity in addition to numerous soluble mediators that 
orchestrate disease activity. SAA has been assumed to play an active part in 
mediating inflammation, not least in RA, but our results clearly argue against 
this. Instead we see elevated SAA levels as a consequence of inflammation 
and as such it is an important biomarker that could be used to effectively 
monitor disease activity. 
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grandmother and grandfather, but also for being fantastic people. 
 
My late parents Inga Marie Nilsson and Sven-Erik Björkman. I know 
you would have been proud of me today. 
 
Per, my brother. No matter whether you are in Malmoe, Burma, Congo or 
Ethiopia, you are always with me, Erik and Johan. 
 
Per, Erik and Johan for showing me what really matters in life. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING  
Samtal mellan författaren och hennes barn (deras frågor i kursiv stil) 
en kväll den 10 mars 2010 i Göteborg. 
 
- Jag har skrivit en bok som sammanfattar det forskningsprojekt som jag hållit på med 
de senaste 6 åren.  
- Va! Börjar den bli klar nu? Vad handlar den om? 
- Jag arbetar ju med en typ av vita blodkroppar som heter neutrofiler, de är viktiga celler 
i vårt immunförsvar som skyddar oss mot främmande organismer.  
- Jaha, varför är de viktiga? Vad händer om man inte har dem, eller har för lite av dem 
då?  
- Ja, det kan vara mycket allvarligt eftersom deras viktigaste roll är att försvara oss mot 
infektioner. 
- Hurdå försvara oss mot infektioner? 
- Jo, de är fagocyter och det betyder att de kan äta upp material som kanske behöver 
rensas upp, t.ex. bakterier” – och på så sätt kan kroppen själv rensar upp en infektion. 
-Menar du att de kan ta sig till min stortå om jag har trampat på en spik som kanske är 
smutsig och har bakterier på sig? 
- Javisst, jag skall försöka förklara. Neutrofilerna bildas i benmärgen och släpps ut i 
blodet allt eftersom i stora mängder, flera miljarder neutrofiler finns i blodet hela tiden. 
Inte nog med det, dessutom är det en en cell som bara lever i några dagar så det betyder att 
det hela tiden behöver produceras nya neutrofiler i benmärgen.  Om det nu är så att du 
trampar på en spik och får ett sår som bli svullet och rött så ”larmar”ämnen från såret 
(bakterier och annat) att här har det skett en skada. Neutrofilerna känner av de här 
larmsignalerna och kan då ”sniffa” sig fram till skadan med hjälp av speciella molekyler 
som man kallar receptorer på sin cellyta. 
- Men spiken kanske inte bara sitter i blodådran, då kan väl inte neutrofilerna göra så 
stor nytta? 
- Jo, det är sant, men neutrofilen är en fiffig cell, för den kan röra sig, typ kravla sig 
fram och det kallas för kemotaxi. Det betyder helt enkelt att den kan ta sig ut från 
blodkärlet och komma precis fram till där skadan sitter. Det kommer att samla sig en hel 
massa neutrofiler där och då uppstår det en inflammation. Man kan säga att detta är 
kroppens sätt att börja läka skadan. 
- De där ämnena du pratar om, larmsignaler, vad är det för några ämnen? 
- Det kan vara bakterier, men det kan också vara andra ämnen som kommer fram ur 
köttet då man skadat sig. 
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- Det är ju bra, då är det en cell som gör nytta. 
- Ja, verkligen, och i de flesta fall går det bra. Men eftersom att den skall ta hand om 
skadliga saker, t.ex. bakterier så innebär ju det att den kan vara ganska så ”ilsken” om ni 
förstår vad jag menar? 
- Jaha, menar du att det är en slags strid som utspelar sig kring den där spiken? 
– Ja, just det, och som ni vet så är det ju så att även om man tar kål på fienden så blir det 
ju ofta skador på saker runt omkring. Det har ni väl märkt när ni spelar CoD?  
-OK! Neutrofilen dödar t.ex. bakterien, och det är bra – men det kan bli skador runt om 
också!? Förresten vad har en spik i foten att göra med ditt jobb? Jag trodde att du jobbade 
med patienter som har ont i lederna? 
-Ja, jag är reumatolog. Och nu glömmer vi spiken i foten. För inflammation, ni vet, 
ansamling av neutrofiler händer hos patienter med ledsjukdomar också. Man vet inte 
riktigt varför man får sådana sjukdomar, men, av okänd anledning uppstår inflammation i 
kroppen och det kan bero på att man reagerar på något inuti sig själv som man egentligen 
inte skulle reagera på. 
- Menar du att ”spiken” kommer inifrån kroppen istället? 
- Mmm.. ungefär. Nu säger vi att inflammationen är igång och det skickas ut signaler 
som säger till neutrofiler att röra sig mot det som är inflammerat. De i sin tur sänder ut 
ännu mer larmsignaler och så är karusellen alltså igång! 
- Vänta lite, var det något sådant som hände när jag hade Kawasaki? 
- Ja, du hade en mycket kraftig inflammation, men som tur är blev du ju helt frisk! 
Patienter som har ledgångsreumatism har mycket inflammation och ett av deras 
larmsignaler är ett protein som heter serum amyloid A. Man kan mäta väldigt höga halter 
av det här proteinet både i blod och i leder hos dessa patienter. 
- Är det ett snällt eller ett elakt protein? 
- Det var en bra fråga! Många tror att det här proteinet som vi kallar för SAA hjälper till 
att förvärra inflammationen just genom att påverka neutrofiler hos patienter med 
ledgångsreumatism.  
- Ja, det tror väl du med? 
- De flesta som säger det använder sig inte av det kroppsegna proteinet utan de köper 
något som kallas för rekombinant protein och det betyder att man framställt det konstgjort  
utanför kroppen i ett laboratorium. Det som är lite speciellt är att det här konstgjort 
framställda SAA proteinet är inte helt likt det proteinet som finns i kroppen. 
- Jaha, spelar det någon roll då? 
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- Ja vi tror det. Det verkar som så att det konstgjort framställda proteinet framkallar 
mycket inflammation när man gör laborationer på det. Det jag vill säga är att det aktiverar 
neutrofiler mycket. Men när jag undersöker blod från patienter med ledgångsreumatism 
som har jättehöga nivåer av SAA så kan jag se att deras neutrofiler inte alls är aktiverade. 
Jag har till och med tittat på neutrofiler som kommer från ledvätska hos sådana här 
patienter. Neutrofilerna där var inte heller så aktiverade…är ni med..? 
- Kanske, men ta det kort en gång till.  
- OK! Vi tror att det SAA som finns i kroppen när man har en pågående inflammation 
mest är en larmsignal, det har ingen egen inflammatorisk effekt, till skillnad från det 
konstgjorda som har mycket inflammatorisk effekt. 
- OK. Vi förstår en del. Är du nöjd med boken? 
- Ja!  
 
